Adaptive Biotechnologies (ADPT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncology Diagnosticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Short Interest
Short interest: 7.56% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Adaptive Biotechnologies (ADPT) Stock Sees Modest Fair Value Lift On MRD Optimism
- Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update
- Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
- NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)
- Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
- Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
- Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.
- Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Adaptive Biotechnologies.
Full ADPT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.